# Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder

> **NCT00329264** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 876 (estimated)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** Quetiapine fumarate

## Key facts

- **NCT ID:** NCT00329264
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 876 (ESTIMATED)
- **Last updated:** 2009-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329264, "Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00329264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*